KIYATEC Announces Addition of Chief Commercial Officer Stacy Chick to Executive Team

New hire will accelerate KIYATEC’s entry into commercial stage

GREENVILLE, SC – September 21, 2021 – The functional precision oncology company KIYATEC, Inc. announced today the addition of Chief Commercial Officer, Stacy Chick, to their Executive Team. Stacy brings over 30 years of successful life sciences commercialization experience in pharmaceutical and oncology molecular diagnostic sales, marketing, market access and reimbursement, business development and policy. Most recently, Stacy served as US Commercial Advisor to several global life sciences companies, investors, and boards. As CCO at KIYATEC she is responsible for building and leading the commercial strategies for clinical testing, beginning with the 3D Predict™ tests.

KIYATEC’s 3D cell culture-based tests are designed to provide oncologists with patient-specific evidence of response to known anti-cancer drugs prior to treatment. This summer, based on positive clinical data released earlier this year showing outcomes improvement, KIYATEC expanded the availability of its 3D Predict™ Glioma test to patients with newly diagnosed or relapsed high-grade glioma (HGG) outside of KIYATEC’s clinical study.

“Drawing on my years of board service as a glioblastoma patient advocate and valuing what the 3D Predict technology can mean to treatment selection for patients and their physicians, I am excited to join KIYATEC’s team and help bring this beneficial test to more oncologists and patients,” said Stacy Chick. “While the 3D Predict Glioma test is the first one that we are launching commercially, several other solid tumor tests are in our rigorous pipeline.”

The 3D Predict™ Glioma test is designed to work within the current treatment timeframe for HGG patients. Since live cells are required for the test, a patient’s oncologist must coordinate sample submission with the timing of the first surgery for newly diagnosed patients, or recurrent surgeries for relapsed patients. Oncologists interested in the potential use of the test to inform their decision-making, or requesting test kits to provide samples, should contact the company at

Matthew Gevaert, KIYATEC CEO and Co-founder said, “We welcome Stacy to our team and are enthusiastic about the commercial launches of the 3D Predict tests under her remarkable leadership. Her commercial life sciences experiences will be a wonderful asset in supporting our efforts to improve cancer drug selection for patients.”

KIYATEC is a functional precision oncology company that measures the response of each patient’s live cancer cells to inform oncologists’ treatment selection decisions. The company’s Clinical Services business offers or is developing clinical tests for high-grade glioma, ovarian, breast, and non-small cell lung cancers, and rare tumors in its CLIA-certified lab. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.

Caroline Wallace